COMP <GO>
NAGE vs UNH // RSI-14 & 200D SMA MOMENTUM
Niagen Bioscience Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: NAGE 8
— UNH 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: UNH
LAST: $2.50 (-1.57%) • MKT CAP: $197.8M
rsi-technicals
43.1
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
rsi-technicals
59.2
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NAGE VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NAGE | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.30% | 88.57% | -24.27 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.80% | 11.47% | +5.33 | NAGE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.2x | 16.4x | -4.25 | NAGE | /valuation <GO> |
| Free Cash Flow Yield | 6.83% | 6.48% | +0.35 | NAGE | /fcf-yield <GO> |
| Operating Margin | 12.60% | 4.82% | +7.78 | NAGE | /operating-margins <GO> |
| Net Profit Margin | 13.40% | 3.14% | +10.26 | NAGE | /net-margins <GO> |
| Revenue Growth (YoY) | 29.90% | 6.46% | +23.44 | NAGE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.40 | 3.12 | +1.28 | NAGE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 43.1 | 59.2 | -16.10 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.6x | 17.7x | -8.14 | NAGE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $197.8M | $368.83B | -$368.63B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NAGE REV | UNH REV | NAGE GROSS % | UNH GROSS % | NAGE FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $129.4M | $447.57B | 64.3% | 88.7% | $13.5M | $16.07B |
| FY 2024 | $99.6M | $400.28B | 61.8% | 88.3% | $12.1M | $20.70B |
| FY 2023 | $83.6M | $371.62B | — | 89.6% | $7.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NAGE // BETA —
UNH // BETA 0.33